Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.10 – $15.12
54% from low
Exchange
OTC Link
OS
INNOVENT BIOLOGICS INC
No one on the platform currently holds IVBXF.
No tracked institution reports a position in IVBXF as of their last filing.
No one on the platform has traded IVBXF yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $19.3B | +48.3% | $1.24 | $1.00–$1.86 | 10.0× | 1 |
| 2027 | $23.5B | +22.0% | $2.08 | $1.68–$3.11 | 6.0× | 1 |
| 2028 | $27.8B | +18.1% | $2.87 | $2.32–$4.30 | 4.3× | 1 |
| 2029 | $35.7B | +28.5% | $4.46 | $3.61–$6.68 | 2.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-03-26 | $0.02 | $-0.00 | -108.3% |
| 2025-08-27 | $0.03 | $0.07 | +173.3% |
| 2025-03-26 | $-0.03 | $0.03 | +179.4% |
| 2024-08-28 | $-0.03 | $-0.03 | +3.2% |
| 2024-03-20 | $-0.07 | $-0.08 | -12.5% |
| 2023-06-30 | $-0.10 | $-0.01 | +87.4% |
| 2022-12-31 | $-0.17 | $-0.12 | +30.7% |
| 2022-06-30 | $-0.15 |
| $-0.10 |
| +36.4% |
| $13.4B |
| — |
| GNMSFGenmab A/S | $310.63 | -0.28% | $19.1B | — |
| SBHMYSino Biopharmaceutical Limited | $13.01 | +0.00% | $11.6B | — |
Source: Financial Modeling Prep · peers by sector/industry